Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

Autor: Phyllis van der Ploeg, Cynthia SE. Hendrikse, Anna MJ. Thijs, Hans M. Westgeest, Huberdina PM. Smedts, M Caroline Vos, Mathilde Jalving, Christianne AR. Lok, Ingrid A. Boere, Maaike APC. van Ham, Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy I. Lalisang, Sandrina Lambrechts, Ruud LM. Bekkers, Jurgen MJ. Piek

Publikováno v: Heliyon, Vol 10, Iss 1, Pp e23170- (2024)

Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alter

Externí odkaz: https://doaj.org/article/ec80d08ac0c84967956ced20e2dd05ff

Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands

Autor: Joosje H. Heimovaara, Ingrid A. Boere, Jorine de Haan, Kristel van Calsteren, Frédéric Amant, Lia van Zuylen, Christine A.R. Lok, C.A.R. Lok, L. van Zuylen, I.A. Boere, F. Amant, C.C.M. Beerendonk, M. Bellido-Casado, J.J. Beltman, M.E.M.M. Bos, J.J. Duvekot, C.G., Gerestein, S. Gordijn, C.J.M. de Groot, M. van Grotel, S.N. Han, B.C. Heeres, M.M. van den Heuvel-Eibrink, A. Houwink, D.R. Huitema, PhW. Koken, L.B. Koppert, P.J. Lugtenburg, P.B. Ottevanger, R.C. Painter, P.M.P. Poortmans, E.M. Roes, L. van der Scheer, C.P. Schröder, B.B.M. Suelmann, K.P.M. Suijkerbuijk, G. van Tienhoven, N.E. van Trommel, J.W. Trum, J. van der Velden, I.J.H. Vriens, P.O. Witteveen

Publikováno v: Heimovaara, J H, Boere, I A, de Haan, J, van Calsteren, K, Amant, F, van Zuylen, L, Lok, C A R, the Dutch Advisory Board for Cancer during Pregnancy, Lok, C A R, van Zuylen, L, Boere, I A, Amant, F, Beerendonk, C C M, Bellido-Casado, M, Beltman, J J, Bos, M E M M, Duvekot, J J, Gerestein, C G, Gordijn, S, de Groot, C J M, van Grotel, M, Han, S N, Heeres, B C, van den Heuvel-Eibrink, M M, Houwink, A, Huitema, D R, Koken, P, Koppert, L B, Lugtenburg, P J, Ottevanger, P B, Painter, R C, Poortmans, P M P, Roes, E M, van der Scheer, L, Schröder, C P, Suelmann, B B M, Suijkerbuijk, K P M, van Tienhoven, G, van Trommel, N E, Trum, J W, van der Velden, J, Vriens, I J H & Witteveen, P O 2022, ' Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands ', European Journal of Cancer, vol. 171, pp. 13-21 . https://doi.org/10.1016/j.ejca.2022.04.040
European Journal of Cancer, 171, 13-21. Pergamon
European Journal of Cancer, 171, 13-21. Elsevier Ltd.
European Journal of Cancer, 171, 13-21. ELSEVIER SCI LTD
European Journal of Cancer, 171, 13-21
European Journal of Cancer, 171, pp. 13-21
European Journal of Cancer, 171, 13-21. Elsevier Limited

Contains fulltext : 252036.pdf (Publisher’s version ) (Closed access) BACKGROUND: Most physicians encounter pregnant women with cancer incidentally, leading to a lack of expertise or confidence to inform and treat these patients based on the most r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb870c0ecb6e659780a111f08cb40158
https://doi.org/10.1016/j.ejca.2022.04.040

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

Autor: Silvia R. Vitale, Floris H. Groenendijk, Ronald van Marion, Corine M. Beaufort, Jean C. Helmijr, Hendrikus Jan Dubbink, Winand N. M. Dinjens, Patricia C. Ewing-Graham, Ramon Smolders, Helena C. van Doorn, Ingrid A. Boere, Els M. J. J. Berns, Jozien Helleman, Maurice P. H. M. Jansen

Publikováno v: Biomolecules, Vol 10, Iss 3, p 415 (2020)

The aim of this study was to determine an optimal workflow to detect TP53 mutations in baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas (HGSOC) patients and to define whether TP53 mutations are suitable

Externí odkaz: https://doaj.org/article/76c9e3e5ee1348d4b952b7c5f009f099

2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205

Autor: Domenica Lorusso, Ignace Vergote, Roisin E O’Cearbhaill, Anne M Westermann, Susana Banerjee, Els van Nieuwenhuysen, David A Iglesias, Dearbhaile Collins, David Cibula, Kristine Madsen, Krishnansu S Tewari, Sandro Pignata, Jean-Francois Baurain, Ingrid A Boere, Hannelore Denys, Camilla Mondrup Andreassen, Ibrahima Soumaoro, Shweta Jain, Christine Gennigens, Bradley J Monk

Publikováno v: Cervical cancer.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b47f157101765046d2752ff11928651
https://doi.org/10.1136/ijgc-2022-esgo.125

The added value of H-2 antagonists in premedication regimens during paclitaxel treatment

Autor: Patricia M. L. A. van den Bemt, Ingrid A. Boere, Roelof W F van Leeuwen, Esther Oomen-de Hoop, Juul M. Cox, Tessa M. Bosch, Ruben Malmberg, Leni van Doorn, Agnes Jager, Ron H.J. Mathijssen

Publikováno v: British Journal of Cancer, 124(10), 1647-1652. Nature Publishing Group

Background: Ranitidine, a histamine 2 blocker, is the standard of care to prevent hypersensitivity reactions (HSRs) caused by paclitaxel infusion. However, the added value of ranitidine in this premedication regimen is controversial. Therefore, we co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6cbfff37ed4074ce982e9b8d1d1b753
https://research.rug.nl/en/publications/298eb27d-ea6a-4185-b5c0-53296ae2c87b